---
openapi: /ja/openapi/calendar_api.spec.yml GET /calendar/fda
---

<ResponseExample>
```json レスポンス (200 OK)
{
  "fda": [
    {
      "commentary": "",
      "companies": [
        {
          "cik": "",
          "id": "659ce7728fadc30001181058",
          "name": "Verastem Oncology",
          "securities": []
        }
      ],
      "created": 1767078664,
      "date": "2025-12-29",
      "drug": {
        "generic": false,
        "id": "6948e41848cd1700014d05f5",
        "indication_symptom": [
          "for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer"
        ],
        "name": "RAMP 203"
      },
      "event_type": "evaluation",
      "id": "69537b08faaadb0001c57f51",
      "nic_number": "",
      "notes": "",
      "outcome": "Verastem Oncology  announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors.",
      "outcome_brief": "",
      "source_link": "https://www.benzinga.com/pressreleases/25/12/b49620354/verastem-oncology-provides-update-on-ramp-203-phase-12-clinical-trial-for-advanced-kras-g12c-mutan",
      "source_type": "Press Release",
      "status": "",
      "target_date": "",
      "time": "16:01:00",
      "updated": 1767078739
    }
  ]
}
```
</ResponseExample>